Investors face a classic choice between AbbVie's steady dividends and Abivax's high-risk, high-reward potential as both target lucrative immunology markets.
A wave of subscription increases from Netflix, Disney, Apple, and others is forcing consumers to rethink their streaming budgets, with ad-supported tiers and strategic bundling emerging as key cost-saving strategies.
A sharp sell-off grips both digital and traditional safe havens, with Bitcoin nearing a critical $80,000 level and gold suffering its worst drop in months, fueled by Fed uncertainty and tech sector anxieties.
Microsoft shares tumbled 12% as investors questioned the return on its massive AI investments, despite strong cloud growth. The volatility has created a surge in bullish options activity, presenting strategic opportunities for long-term believers.
After the COVID-19 windfall subsided, Pfizer CEO Albert Bourla is steering the pharmaceutical giant into a high-stakes, $23 billion pivot to cancer research. Facing a looming patent cliff and plummeting vaccine revenue, Bourla is betting on scientific innovation to secure the company's future—and redefine cancer treatment.
First Bank Corp. has entered into a definitive agreement to merge with Russellville-based First State Bank, a strategic move set to deepen the holding company's roots in the Arkansas River Valley region while preserving the community bank's local identity.
Despite a recent price target cut from Morgan Stanley, analysts maintain that Oracle's strategic investments in GPU-as-a-Service and its deepening ties with TikTok position it for long-term cloud growth, even as capital expenditures weigh on short-term earnings.
Months after the 'Crypto Black Friday' crash, allegations of platform instability and market manipulation continue to dog Binance, sparking fierce debate about trust and power in the digital asset space.
Wix.com Ltd. has launched a major share repurchase program as its stock trades near multi-year lows. While analysts have trimmed price targets, many maintain bullish ratings, citing significant upside potential and a more resilient outlook for SaaS companies in the face of AI disruption.
In a significant shift from its long-standing marketing playbook, Pizza Hut will not advertise during NBC's Super Bowl pre-game coverage this year, ending a tradition that spanned over a decade. The move comes as the chain undergoes a strategic review and reallocates its ad budget toward other sports and partnerships.
Despite posting no revenue, Voltaic Strategic Resources (ASX:VSR) has seen its share price skyrocket 300% in the past year. We analyze whether its cash reserves can fuel further growth or if a reckoning is on the horizon.
While an IRS extension grants an extra six months to file, experts caution that the April 15 payment deadline is non-negotiable. We break down the process, benefits, and common pitfalls for the millions considering this option.
The global lifestyle retailer MINISO continues its aggressive capital return strategy, repurchasing millions of shares under a Rule 10b5-1 program as analysts remain bullish on the stock's outlook.
U.S. wheat futures declined across major exchanges on Friday, with Chicago, Kansas City, and Minneapolis contracts all trading lower. Despite the pullback, export sales data remains robust, running ahead of last year's pace.
Soybean prices extended their decline on Friday, pressured by lackluster export sales data and a broader commodity sell-off. With key commitments lagging last year's pace, traders are now looking ahead to next week's crush data for signs of domestic demand strength.
A week of significant stock swings saw Lockheed Martin and Texas Instruments surge on strong outlooks, while Humana plunged on regulatory headwinds. Here’s what drove the action and what analysts are saying.
While stocks priced between $10 and $50 often signal companies past their initial hurdles, some still grapple with unproven models and market volatility. We examine three such stocks where the risk may outweigh the potential reward.
While Wall Street analysts are overwhelmingly bullish on several stocks, their optimistic price targets often come with a caveat. We examine one company where the enthusiasm appears justified and two where underlying challenges suggest a more cautious approach.
While the healthcare sector has surged 17.4% in six months, outpacing the S&P 500, regulatory headwinds and valuation concerns demand a selective approach. We examine one stock with a durable edge and two facing significant challenges.
While stocks priced between $10 and $50 often signal companies past their initial hurdles, they can also mask underlying vulnerabilities. We analyze three such stocks—Figs, Array Technologies, and Kforce—that currently present significant risks to investors, despite their seemingly accessible price tags.
